Illustrative image – not actual.Unichem Laboratories has planned to
set up a Rs.30 crore active pharmaceutical ingredient (API) plant at Baddi in
Himachal Pradesh.
The new project, primarily focused
on export markets, will be set up adjacent to the company’s existing
formulations unit at Baddi which already has in place several international
approvals. The new unit will be funded through internal accruals.
The plant, which will get income tax
exemptions and excise duty benefits from Himachal Pradesh government, is likely
to be ready by 2005.
Unichem is also in the process of
acquiring an US FDA-approved API plant in India. Meanwhile, the company recently
modernized its Ghaziabad unit entailing capital expenditure of Rs.33 crore. The unit, which is undergoing inspection by
various international agencies, has been revamped into a multipurpose facility
producing the entire range of formulations including tablets, capsules, syrups
injectibles. Unichem’s other units are
located at Goa and Roha in Maharashtra.
API accounts for around 12 per cent
of the company’s turnover, while formulations contribute 82 per cent. The
company manufactures a range of APIs including anti-amoebics,
anti-hypertensives, anti-depressants, muscle relaxants, anti-asthamatics and
de-congestants among others.
